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Introduction
Multiple sclerosis (MS) is a chronic autoim-
mune inflammatory disease of the central nerv-
ous system (CNS) that mainly affects young 
adults and may lead to significant disability over 
time. Since the first documented case of MS in the 
nineteenth century the knowledge regarding the 
pathophysiology of the disease has significantly 
advanced. The inflammatory cells in MS have 
been well described and include CD4 and CD8 
T lymphocytes, microglia and macrophages 
[Goverman, 2011]. Also humoral immunity has 
been described as an important component in 
the pathophysiology of MS [Boster et al. 2010].
Within the past 30 years new and effective 
therapies have been developed that decreased 
clinical relapses, reduced new T2 and gadolinium-
enhancing (Gad+) lesions and aim to halt the 
progression of disease. Since the US Food and 
Drug Administration (FDA) approval of the first 
disease-modifying therapy (DMT) in 1993, 
interferon (IFN)-β1b (Betaseron), which was 
also approved in Europe in 1995 under the name 
of Betaferon, we now have a total of eight FDA-
approved therapies for MS, including an oral 
agent and a single agent approved for secondary 
progressive MS (SPMS) (Table 1). Of note, there 
are two agents approved by the European 
Medicines Agency (EMA) for the treatment of 
SPMS, mitoxantrone and IFN-β1b (Betaferon/
Extavia). All first-line injectable agents have 
been studied in clinically isolated syndrome 
(CIS) and have demonstrated decreased risk of 
conversion into clinically definite MS (CDMS) 
(Table 2) [Kappos et al. 2006; Jacobs et al. 2000; 
Comi et al. 2001, 2009, 2012a]. So far there is 
no effective therapy to halt progression of disease 
and reduce disability in primary progressive MS 
(PPMS).
There are many new agents in the pipeline which 
will bring great choices into the MS pharmaco-
logical armamentarium (Table 3).
FDA- and EMA-approved therapies
Interferon β
IFNs are a family of proteins that play a role in 
the body’s natural defense against microbial, neo-
plastic and viral insults and have a role in regu-
lating the immune response. IFN-β impacts the 
immune system in several ways, such as decreas-
ing major histocompatibility complex (MHC) 
class II expression, upregulation of interleukin 10 
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(IL-10) production, and decreased T helper (Th)-1 
and Th17 production, which leads to an overall 
anti-inflammatory effect [Kieseier, 2011; Kappos 
et al. 2007].
Subcutaneous interferon β1b (Betaseron, Bayer 
Schering Pharma AG/Betaferon, Bayer Schering 
Pharma AG/Extavia, Novartis Pharmaceuticals 
Corp.). The pivotal phase III trial using IFN-β1b 
was a randomized, double-blind, placebo-con-
trolled, multicenter trial of 372 patients with 
RRMS over 2 years. This trial demonstrated a 
34% reduction in overall relapses compared with 
placebo. More specifically, there was a 50% reduc-
tion in annualized relapses classified as moderate 
to severe in the treatment group. Patients receiv-
ing IFN-β1b were also found to have a lower T2 
lesion volume and decreased accumulation of new 
lesions [IFNB Multiple Sclerosis Study Group. 
1993]. Each of the IFN-β therapies, as well as 
glatiramer acetate, has been shown to delay con-
version to CDMS in patients with CIS (Table 2). 
In the 5-year active treatment extension of the 
BENEFIT trial, the effects of early versus delayed 
treatment with IFN β1b were investigated. This 
study showed the risk of conversion to CDMS 
remained lower in the group receiving early treat-
ment; 46% compared with 57% of patients con-
verting from CIS to CDMS [hazard ratio (HR) 
0.63; 95% confidence interval (CI) 0.48–0.83; log 
rank test p = 0.003) [Kappos et al.2009].
Intramuscular interferon β1a (Avonex, Biogen Idec, 
Inc.). In the pivotal trial including 301 patients 
Table 1. Current Food and Drug Administration/European Medicines Agency approved therapies for multiple 
sclerosis (MS)
Disease-modifying 
therapy
Dose/route Monitoring labs/tests Side effects*
IFN-β1a (Avonex) 30 μg intramuscularly 
weekly
CBC, LFTs, TSH Flu-like symptoms, 
depression, thyroid 
dysfunction, liver enzymes 
abnormalities
IFN-β1a (Rebif) 22 or 44 μg 
subcutaneously three 
times a week
CBC, LFTs, TSH Skin site reactions, flu-like 
symptoms, depression, 
thyroid dysfunction, liver 
enzymes abnormalities
IFN-β1b 
(Betaseron/
Betaferon/Extavia)
250 μg subcutaneously  
every other day
CBC, LFTs, TSH Skin site reactions, flu-like 
symptoms, depression, 
thyroid dysfunction, liver 
enzymes abnormalities
Glatiramer acetate 
(Copaxone)
20 mg subcutaneously 
once a day
None Skin site reactions, 
immediate postinjection 
reaction, lipoatrophy
Mitoxantrone 12 mg/m2 intravenously 
over 30 min every 
3 months with a lifetime 
cumulative dose of no 
more than 140 mg/m2; 
frequency may vary
CBC, LFTs, U/A, LVEF Hair loss, cardiotoxicity, 
leukemia, infertility, 
increased risk of 
infections, leukopenia, 
anemia, nausea, vomiting, 
thrombocytopenia
Natalizumab 
(Tysabri)
300 mg intravenously 
every 28 days
CBC, LFTs Transient headache fatigue, 
recurrent UTIs, PML, 
hypersensitivity reaction
Fingolimod 0.5 mg orally once a 
day
CBC, LFTs, screen 
for macular edema
First-degree AV block with 
first dose, bradycardia, 
macular edema, shingles, 
PF dysfunction in selected 
patients, skin cancer, back 
pain
AV, atrioventricular; CBC, complete blood count; IFN, interferon; LFT, liver function test; LVEF, left ventricular ejection 
fraction; PML, progressive multifocal leukoencephalopathy; PF, pulmonary function; TSH, thyroid-stimulating hormone; 
U/A, urinalysis; UTI, urinary tract infections.
*Selection of side effects, not full side effects profile.
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with RRMS, IFN-β1a intramuscularly was shown 
to delay time to progression of disability with 
fewer treated subjects experiencing disability pro-
gression (21.9% versus 34.9%; p = 0.02) com-
pared with placebo. Annualized relapse rates 
(ARRs) over a 2-year period were also lower com-
pared with placebo (ARR 0.61 versus 0.90; p = 
0.03). The accumulation of Gad+ lesions was also 
reduced; however, T2 lesion volume was not sig-
nificantly different between the two groups at 2 
years [Jacobs et al. 1996].
Subcutaneous interferon β1a (Rebif, EMD Serono, 
Inc.). The Prevention of Relapses and Disabil-
ity by Interferon β-1a Subcutaneously in Mul-
tiple Sclerosis (PRISMS) trial was a 2-year 
randomized, double-blind, placebo-controlled, 
multi-centered trial of 560 patients with RRMS. 
Subjects treated with either the 22 or 44 μg dose 
of IFN-β1a subcutaneously showed a significant 
reduction in ARRs compared with placebo, 27% 
and 33% respectively. Both treatment groups 
showed a significant reduction in the number of 
new or enlarging T2 lesions; 67% reduction in 
the 22 μg group and 78% reduction in the 44 μg 
group [PRISMS Study Group, 1998]. An exten-
sion study utilizing a crossover design in which 
placebo-treated patients were randomized to 
either 22 or 44 μg of IFN-β1a subcutaneously 
after 2 years revealed patients in both active 
treatment groups for the entire 4 years contin-
ued to show significantly lower number of relapses 
per year [PRISMS Study Group, 2001]. IFNs 
have immunogenic properties and treated indi-
viduals may develop binding and neutralizing 
antibodies (NAbs) to these products. NAbs may 
develop with the use of all formulations of IFN-
β; however, they are found more commonly with 
the high-dose, high-frequency IFNs (IFN-β1b 
and IFN-β1a subcutaneously). The issue of 
NAbs is controversial; however, a panel of 
experts met at the Neutralizing Antibodies on 
Interferon Beta in Multiple Sclerosis (NABI-
NMS) consortium in 2009 in attempts to for-
mulate a practical approach to the evaluation 
and incorporation of information regarding 
NAbs in the treatment of MS. The group pro-
posed that both the NAb titer and clinical status 
of the patient should be considered in the deci-
sion regarding the impact of the presence of 
NAbs on changing DMTs. They also suggested 
reevaluation of the NAbs status prior to making 
a change in therapy unless patients were clearly 
performing poorly clinically [Polman et al. 2010].
Glatiramer acetate
Glatiramer acetate (GA) (Copaxone, Teva Neuro-
science North America / Teva Pharmaceuticals) 
is a first-line therapy for relapsing forms of MS 
Table 2. Pivotal trials for approval of disease-modifying therapies in clinically isolated syndrome
Trial Drug Result Reference
BENEFIT IFN-β1b Conversion risk at 2 years 28% 
with interferon β-1b versus 
45% with placebo
Kappos et al. [2006]
CHAMPS IFN-β1a 
intramuscularly
Conversion risk at 2 years 
was 35% with interferon β-1a 
intramuscularly versus 50% 
with placebo
Jacobs et al. [2000]
ETOMS IFN-β1a 
subcutaneously
Conversion risk at 2 years 
was 34% with interferon β-1a 
subcutaneously versus 45% 
with placebo
Comi et al. [2001]
REFLEX IFN-β1a 
subcutaneously
Conversion risk at 2 years 
was 20.6% for three times per 
week dose, and 21.6% for once 
a week dose versus placebo
Comi et al. [2012]
PreCISe Glatiramer acetate Conversion risk at 2 years was 
25% with glatiramer acetate 
versus 43% with placebo
Comi et al. [2009]
BENEFIT, Betaseron/Betaferon in newly emerging multiple sclerosis for initial treatment; CHAMPS,  the controlled high 
risk Avonex multiple sclerosis trial; ETOMS, early treatment of multiple sclerosis; IFN, interferon; PreCISe, effect of 
glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome; 
REFLEX, REbif FLEXible dosing in early MS.
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and CIS. GA contains an incalculable number 
of active amino acid sequences and is composed 
of a large number of synthetic peptides. The 
usual dose of GA is 20 mg subcutaneously once 
a day.
The mechanism of action (MOA) of GA is not 
completely understood, but consists of an antigen-
presenting cell (APC) incorporating peptides of 
GA and presenting them to a lymphocyte, similar 
to the process of a vaccine. This process creates a 
unique population of lymphocytes circulating in 
the blood which are responsive to GA. It inhibits 
the multiplication of human lymphocytes that 
are capable of reacting to myelin basic protein. 
Researchers have been able to show that GA 
binds directly to the portion of the APC that is 
required to stimulate the T lymphocyte, thus 
Table 3. Multiple sclerosis emerging therapies.
Current agents 
in the pipeline
Mechanism of 
action
Phase Administration Results Adverse effects
Laquinimod May modulate  
Th1 to Th2  
cytokine shift
III Oral
0.6 mg daily
23% reduction in 
relapse rate; 37% 
reduction in contrast 
enhancing lesions
LFT elevation
Teriflunomide Inhibits DNA 
pyrimidine 
synthesis in dividing 
cells such as T and 
B cells
III Oral
7 and 14 mg 
daily
61% reduction in 
contrast enhancing 
lesions, reduces 
ARR by 30%, 
reduces disability 
progression by 
23–30%
Nasopharyngitis, 
headache, diarrhea, 
fatigue, back 
pain, influenza, 
hair thinning, LFT 
elevation, nausea, 
UTI
Dimethyl 
fumarate  
(BG-12)
Modulates 
oxidative pathways 
and decreases 
autoimmunity
III Oral
120–240 mg 
three times a 
day
69% reduction in 
contrast enhancing 
lesions (phase II 
trial); DEFINE phase 
III trial showed 
53% reduction in 
ARR; 38% reduction 
in disability 
progression, and 
reduced disability 
progression in  
2 years by 49%
Diarrhea, cramps, 
LFT elevation, nausea 
and flushing
Alemtuzumab Antibody binds 
CD52 to cause 
destruction of 
circulating immune 
cells
III Intravenous 
infusion
12 or 24 mg daily 
for 5 days on 
month 0 and 12 
or 24 mg daily 
for 3 days on 
month 12
Up to 75% reduction 
in sustained 
accumulation 
disability; up to 74% 
reduction in relapse 
rate
Immune 
thrombocytopenic 
purpura, autoimmune 
thyroid-related 
problems, headaches, 
flushing
Daclizumab Block the IL-2 
receptor/ 
anti-CD25
II Subcutaneous 
2 mg/kg every 2 
weeks
72% reduction in 
contrast enhancing 
lesions, decreased 
disease progression 
by up to 57% in 
1 year, decreased 
ARR by 50–54%
Infusion reaction, 
serious skin rash, 
lymphadenopathies, 
LFT abnormalities, 
liver toxicity, 
diarrhea, 
constipation
Ocrelizumab Antibody targets 
CD20 and mediates 
destruction of  
B cells
II 600 mg, 
2000 mg 
intravenous 
infusions
Reduced brain 
lesions by 89% and 
96%, reduced ARR 
by 80% and 73%
Systemic 
inflammatory 
response (one lethal 
case), infusion site 
reactions
ARR, annualized relapse rate; DEFINE, efficacy and safety of oral BG00012 in relapsing remitting multiple sclerosis; HZV, Herpes Zoster 
virus; LFT, liver function test; Th, T helper; UTI, urinary tract infection.
 W Castro-Borrero, D Graves et al.
http://tan.sagepub.com 209
blocking direct immunologic attack. It was in the 
late 1980s that the immunologic concept of Th1 
(proinflammatory) and Th2 (anti-inflammatory) 
lymphocytes gained momentum. These two types 
of lymphocytes can be identified by the chemicals 
that they manufacture and then secrete. These 
chemicals are known as cytokines, and can be 
divided into inflammatory and proinflammatory. 
In 1997, Aharoni and colleagues published a 
paper that described how GA could stimulate the 
production of Th2 (anti-inflammatory) cells that 
inhibited the inflammatory response by secret-
ing anti-inflammatory cytokines [Aharoni et al. 
1997]. The GAs’ effect begins in the peripheral 
tissues in a population of specific lymphocytes 
which circulate in the blood and are capable of 
migrating into the CNS tissue by crossing the 
blood–brain barrier (BBB). These cells then 
encounter fragments of several myelin proteins 
that stimulate the glatiramer cells to multiply and 
begin to produce anti-inflammatory cytokines. 
Since the glatiramer-activated lymphocytes can 
suppress inflammation under way in the diseased 
area of CNS tissue, this process has been given 
the name bystander suppression [Johnson, 2010]. 
To date, data suggest that GA treatment is associ-
ated with a broader immunomodulatory effect on 
cells of not only the innate but also the adaptive 
immune system. Recent investigations indicate 
that GA treatment may also promote regulatory 
B-cell properties [Lalive et al. 2011].
GA has a relatively narrow adverse effect profile. 
Most frequently patients complain of mild pain 
and pruritis at the injection site. Lipoatrophy and 
skin site reactions are also seen and may lead to 
discontinuation of therapy. A transient reaction 
called immediate postinjection reaction consists 
of chest tightness, flushing and dyspnea begin-
ning soon after the injection and lasting no longer 
than 20 min. If no history or evidence of coronary 
artery disease, the patient can be reassured that 
such a reaction is benign [DiPiro et al. 2005].
Multicenter trials with GA have demonstrated 
statistically significant reductions in mean ARR 
that are comparable to those of the IFNs [DiPiro 
et al. 2005]. In two recent studies the efficacy of 
GA was compared with high-dose/high-frequency 
IFN-β. In the Rebif versus Glatiramer Acetate in 
Relapsing MS Disease (REGARD) study [Mikol 
et al. 2008], subcutaneous IFN-β1a was compared 
with GA, and in the Betaseron/Betaferon Efficacy 
Yielding Outcomes of a New Dose (BEYOND) 
study [O’Connor et al. 2009], subcutaneous 
IFN-β1b was compared with GA. In both trials, 
there was no significant difference between IFN 
and GA in the primary endpoints or in any clini-
cal endpoints, although some differences in mag-
netic resonance imaging (MRI) measures of 
disease activity have been claimed.
The results from a 15-year analysis of the US 
prospective open-label study of GA indicate that 
long-term continuous use is safe. It also indicates 
that the majority of patients continuing on GA 
therapy in the study have had few relapses and 
minimal disease progression. Of the initial 232 
patients that received at least one GA dose since 
study initiation in 1991, only 100 (43%, ongoing 
cohort) patients continued. Of the 100 patients 
receiving continuous GA as sole immunomodula-
tory therapy for 15 years (mean disease duration 
of 22 years and mean patient age of 50 years) have 
not transitioned to SPMS, 57% have retained sta-
ble or improved the Expanded Disability Status 
Scale (EDSS) scores over the course of the study 
and 82% remain ambulatory without mobility aids. 
There was no occurrence of any unforeseen adverse 
events in patients receiving GA therapy. The study 
will continue for 20 years of prospective follow up 
[Ford et al. 2010].
Mitoxantrone
Mitoxantrone is an anthracenedione initially 
developed as an anti-neoplastic agent that reduces 
lymphocyte proliferation. Mitoxantrone interca-
lates into DNA strands, inducing strand breakage 
and inhibition of the DNA repair enzyme topoi-
somerase II. It is an immunosuppressive agent 
used as a second-line treatment for SPMS, pri-
mary relapsing multiple sclerosis and worsening 
RRMS. Mitoxantrone was approved for the treat-
ment of SPMS based on the study by Hartung 
and colleagues [Hartung et al. 2002].
Several studies have shown it to be efficacious in 
reducing exacerbations and number of Gad+ 
lesions on MRI, and it seems to have effects on 
disease course up to 5 years after discontinuing 
therapy [Martinelli et al. 2009; Goodin et al. 2003]. 
Mitoxantrone is given as an intravenous infusion 
over 30 min every 3 months at 12 mg/m2 for a 2- 
to 3-year period with a maximum cumulative dose 
of 140 mg/m2. Common side effects include alo-
pecia, nausea and vomiting, an increased risk of 
infection (particularly urinary and respiratory 
tracts infections) and amenorrhea. Mitoxantrone, 
though effective, remains second line due to its 
Therapeutic Advances in Neurological Disorders 5 (4)
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risk of two serious adverse effects that can occur 
at any time after the first dose is given. The first, 
acute leukemia has an incidence of approximately 
0.81% [Marriott et al. 2010]. Regular monitor-
ing of complete blood counts is recommended. 
Mitoxantrone can also cause decreased left ven-
tricular ejection fraction (LVEF) and congestive 
heart failure at a rate of approximately 12% and 
0.4%, respectively [Marriott et al. 2010]. To 
monitor cardiotoxicity, a baseline LVEF must be 
obtained and any patient with an ejection fraction 
less than 50% should not receive mitoxantrone. 
It was previously believed that cardiotoxicity could 
only occur with cumulative doses over 96–140 
mg/m2; however, several reports of cardiotoxicity 
below this threshold have caused the FDA to rec-
ommend monitoring cardiac function before every 
infusion. The therapy must be discontinued if the 
LVEF ever falls below 50% or decreases by 10% 
[Martinelli et al. 2009].
Natalizumab
Migration of leukocytes from the vasculature 
into the parenchyma involves the interaction 
between leukocyte adhesion molecules and their 
complementary ligands on vascular endothelial 
cells. Leukocyte integrins are heterodimeric gly-
coproteins that contain an α and β chain 
[Ransohoff, 2007]. Vascular cell adhesion mole-
cule 1 (VCAM-1) is expressed on the surface of 
vascular endothelial cells in the blood vessels 
within the CNS and interacts with α4β1 integrin 
on lymphocytes to allow for extravasation across 
the BBB. Also, the interaction of α4β1 integrin 
with fibronectin and osteopontin may modulate 
the survival, priming and activation of leukocytes 
that have entered into the parenchyma of the 
brain and spinal cord. Natalizumab (Tysabri, 
Biogen Idec, Inc.) contains humanized immuno-
globulin G4κ monoclonal antibodies against leu-
kocyte α4 integrins, including α4β1 and α4β7 
integrins, and blocks binding to their endothelial 
receptors (VCAM-1 and mucosal addressin cell 
adhesion molecule 1, respectively) [Polman et al. 
2006]. By blocking α4 integrins, natalizumab 
inhibits the migration of leukocytes into the 
brain, which results in reduced inflammation.
Natalizumab was evaluated for the treatment 
of RRMS in two phase III clinical trials. The 
Natalizumab Safety and Efficacy in relapsing 
remitting multiple sclerosis (AFFIRM) study 
evaluated 942 patients who were randomly 
assigned to receive natalizumab versus placebo 
every 4 weeks for 2 years. The primary endpoints 
were the rate of clinical relapse at 1 year and 
the rate of sustained progression of disability, 
measured by the EDSS, at 2 years. Natalizumab 
reduced the risk of sustained disability by 42% 
over 2 years (HR 0.58; 95% CI 0.43–0.77; p < 
0.001). It reduced the rate of clinical relapse at 
1 year by 68% (p < 0.001). MRI scans were 
obtained at baseline, 1 year and 2 years. Treatment 
with natalizumab resulted in an 83% reduction of 
new or enlarging hyperintense T2 lesions over 2 
years (mean number of lesions 1.9 with natali-
zumab and 11 with placebo; p < 0.001). There 
were 92% fewer Gad+ lesions in the natalizumab 
group than in the placebo group at 1 and 2 years 
(p < 0.001). There was also a significant effect on 
Gad+ lesions seen after 6 weeks of natalizumab 
treatment [Polman et al. 2006].
The Safety and Efficacy of Natalizumab in com-
bination with IFN-β1a in patients with RRMS 
(SENTINEL) trial was a 2-year phase III trial 
evaluating treatment with natalizumab or placebo 
in combination with IFN-β1a. The primary end-
points were the rate of clinical relapse at 1 year 
and accumulative probability of disability pro-
gression, measured by the EDSS, at 2 years. The 
study showed that treatment with both drugs was 
more effective than treatment with IFN-β1a 
alone. Patients on combination treatment were 
less likely to have sustained disability progression 
(23% versus 29%) and were more likely to remain 
relapse free (61% versus 37%). Combination 
treatment resulted in fewer new or enlarging T2 
lesions (0.9 versus 5.4; p < 0.001) [Rudick et al. 
2006]. The study ended a month early due to the 
occurrence of progressive multifocal leukoen-
cephalopathy (PML) in two patients who received 
natalizumab with IFN-β1a.
The most notable potential adverse effect of natal-
izumab treatment is the development of PML. 
Following the observation that three patients 
treated with natalizumab developed PML, it was 
withdrawn from the market in February 2005 
and reintroduced in July 2006 as monotherapy 
treatment for RRMS. The original risk of PML 
was estimated to be approximately one per 1000 
patients receiving natalizumab [Berger, 2010]. As 
of 4 January 2012, approximately 96,582 patients 
have received natalizumab since it was marketed 
and there have been 201 confirmed cases of PML 
worldwide. Approximately 20% of patients who 
have developed PML have died. Those that sur-
vived have varying levels of disability, ranging 
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from mild to severe. Fewer patients treated and 
wide confidence intervals result in questionable 
estimates beyond 30 months of treatment.
PML is a rare demyelinating disease of the 
brain due to the John Cunningham (JC) virus. It 
is almost always seen in association with an 
underlying immunosuppressive condition. The 
precise explanation for the increased risk of PML 
with natalizumab therapy remains unknown.
In the natalizumab clinical trials, there was a 
small increase in the rate of infections, including 
herpes infections, pneumonia and urinary tract 
infections. There were no other opportunistic 
infections or increase cases of cancer reported 
[Ransohoff, 2007]. Post-release monitoring dis-
closed one case of fatal herpes encephalitis, 
one nonfatal case of herpes meningitis, crypto-
sporidium gastroenteritis, pneumocystis carinii 
pneumonia, varicella pneumonia and mycobac-
terium avium intracellular complex pneumonia 
[Ransohoff, 2007; Gorelik et al. 2010].
Natalizumab infusions were complicated by seri-
ous hypersensitivity reactions, including fever, 
rash and anaphylaxis, in less than 1% of patients 
and less serious infusion reactions in about 4% of 
patients [Ransohoff, 2007; Polman et al. 2006; 
Rudick et al. 2006]. Patients with infusion reac-
tions were more likely to have persistent NAbs. 
The presence of antibodies lessoned natalizum-
ab’s clinical efficacy and resulted in clinical and 
radiographic disease activity equivalent to patients 
in the placebo group [Ransohoff, 2007].
Natalizumab is an extremely effective therapy 
for RRMS and is licensed for highly active naïve 
patients. Due to the potential risk of PML and 
other opportunistic infections, it is typically 
reserved for patients with clinically or radio-
graphically extremely active disease either as 
initial therapy or when initial therapy has been 
ineffective or poorly tolerated. Treatment with 
natalizumab requires rigorous ongoing clinical 
surveillance. To minimize the risk of PML, 
patients beginning treatment should have no 
history of immunosuppressive medications in 
the preceding 3 months and should not have 
other conditions that may compromise cell-
mediated immunity. The FDA and EMA rec-
ommend the use of the JC virus antibody for 
risk stratification on all patients on Tysabri. The 
risk of PML increases after 24 months on ther-
apy, if there has been prior immunosuppressant 
use and the presence of JC virus antibody. 
Patients with positive JC virus antibody, prior 
treatment with an immunosuppressant and who 
have received more than 24 doses of Tysabri 
have an estimated risk of PML of 9–11/1000. 
However, patients without any of those risk fac-
tors for PML have a risk of PML of less than 
0.1 per 1000 [Sorensen et al. 2012].
Fingolimod
Fingolimod is an oral sphingosine-1 phosphate 
(S1P) receptor modulator. It was approved by the 
FDA in September 2010 as first-line therapy for 
RRMS. However, the EMA has recommended 
that its use be limited to those whose condition 
fails to respond to first-line therapy or only in 
cases of severe, rapidly developing cases of MS. It 
acts as a sphingosine analogue, binding to the 
S1P1 receptor on lymphocytes leading to inter-
nalization and downregulation of their expression 
and thereby preventing the egression of lympho-
cytes from the lymph nodes. Additionally, through 
interactions with S1P receptors on neural cells, 
fingolimod has been shown to have potentially 
neuroprotective effects in the animal experimen-
tal autoimmune encephalomyelitis model [Foster 
et al. 2007; Coelho et al. 2007; Miron et al. 2008].
In the 24-month phase III FTY720 Research 
Evaluating Effects of Daily Oral therapy in 
Multiple Sclerosis (FREEDOMS) trial compar-
ing placebo with oral fingolimod at doses of 1.25 
mg and the now FDA-approved 0.5 mg daily 
dose, there was a significant reduction in ARR 
with both doses of fingolimod (0.16 at 1.25 mg 
and 0.18 at 0.5 mg) compared with placebo 
(0.40) which represented a relative reduction of 
60% and 54%, respectively. Furthermore, fingoli-
mod also reduced the risk of disability progres-
sion with a probability of disability progression 
(confirmed after 3 months) of 17.7% at the 0.5 
mg dose and 16.6% at the 1.25 mg dose com-
pared with 24.1% with placebo. Almost 90% of 
patients receiving fingolimod, at either dose, were 
free of enhancing lesions over the course of 2 
years and approximately 50% were free of new or 
enlarging T2 lesions [Kappos et al. 2010].
The Trial Assessing Injectable Interferon versus 
FTY720 Oral in RRMS (TRANSFORMS) com-
paring fingolimod with intramuscular INF-β1a 
showed a 52% relative reduction in ARR in the 
patients treated with fingolimod 0.5 mg versus 
IFN. This study showed a similar beneficial 
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effect on MRI markers compared with IFN-β1a; 
however, there was no statistically significant 
difference in the disability progression between 
the fingolimod and IFN-β1a groups [Cohen et al. 
2010].
Despite its efficacy, there are additional safety 
concerns compared with the injectable therapies. 
Data from the two pivotal trials showed an 
increased risk of infections, cardiovascular effects, 
including bradycardia and atrioventricular (AV) 
block (first and second degree) with initial dosing 
and macular edema. Each of these was more 
common with the higher 1.25 mg dose. Of note, 
there were two deaths related to infections in sub-
jects receiving fingolimod at the 1.25 mg dose in 
TRANSFORMS. One death was secondary to a 
dissemination varicella zoster infection and the 
second was related to herpes simplex encephalitis. 
While herpes virus infection has been seen at 
the 0.5 mg dose, cases tended to be mild and 
were not found to occur at a higher rate than the 
control arm [Cohen et al. 2010].
The EMA recently recommended increased 
patient monitoring during the first dose of fin-
golimod, including electrocardiogram monitor-
ing before treatment and then continuously for 
the first 6 h after the first dose is administered, 
and measurement of blood pressure and heart 
rate every hour over the same 6 h.
Off-label therapies
Immunosuppressive agents, chemotherapies and 
various mAbs have been used off label for many 
years as DMTs in MS but the potential benefits 
of these therapies are limited by systemic adverse 
events, such as increased risk of malignancy and 
opportunistic infections. These agents have been 
used in patients who are refractory to or cannot 
tolerate the side effects of IFN-β and GA, cannot 
afford FDA-approved therapies, or need intensifi-
cation of therapy (i.e. used in combination with 
IFN-β or GA). Also limiting the use of these med-
ications is the lack of large-scale, controlled trials, 
validating their efficacy.
Mycophenolate mofetil
Mycophenolate mofetil (MMF; Cellcept, Roche 
Laboratories, Nutley, NJ, USA) is FDA and EMA 
approved for preventing rejection of cardiac, liver 
and renal transplants. MMF undergoes rapid and 
complete metabolism to mycophenolic acid (MA), 
which is the active metabolite. MA is a potent, 
selective, noncompetitive and reversible inhibitor 
of inosine 5’ monophosphate dehydrogenase type 
II. MA inhibits the de novo synthesis pathway of 
guanosine nucleotides without being incorporated 
into DNA. Because T and B lymphocytes are 
critically dependent for their proliferation on de 
novo synthesis of purines, while other cell types 
can utilize salvage pathways, MA has potent cyto-
static effects on lymphocytes. MA inhibits prolif-
erative responses of T and B lymphocytes to both 
mitogenic and allospecific stimulation. MA also 
suppresses antibody formation by B lymphocytes 
[Product information: Cellcept, 2009].
Potential side effects include hypertension, back-
ache, abdominal pain, diarrhea, nausea, elevated 
transaminases, vomiting, anxiety and tremor. 
Serious side effects include gastrointestinal bleed-
ing, thrombocytopenia, skin cancer, opportunistic 
infection and PML. Increased susceptibility to 
infection and the possible development of lym-
phoma may result from immunosuppression.
A retrospective review of experience in treating 
79 patients with MS with MMF showed that 
this agent was well tolerated by the majority of 
patients. Patients were initiated on 500 mg twice 
a day, which was titrated up by 500 mg weekly 
to a maximum of 1000 mg twice a day. While the 
observations were uncontrolled, some of the 
patients demonstrated either stabilization or 
improvements in their activities of daily living, 
ambulation and relapse rate [Frohman et al. 
2004]. In a randomized, MRI-blinded, parallel 
group, pilot trial of MMF compared with IFN-
β1a, both drugs appeared safe and well toler-
ated in the majority of patients. The trial also 
showed a trend toward a lower accumulation of 
combined active MRI lesions. MMF showed a 
nonstatistically significant increase in infections 
[Frohman et al. 2010]. The dose generally used 
in patients with RRMS is 1000 mg twice daily. 
Large, randomized clinical trials are needed to 
better evaluate the safety and efficacy of this 
agent in patients with MS.
Azathioprine
Azathioprine is FDA approved for rejection proph-
ylaxis (as monotherapy or adjunct) of renal trans-
plant and rheumatoid arthritis (RA). Although 
not FDA approved, it has been used in the USA 
to treat MS since 1971 [La Mantia et al. 2007]. 
Azathioprine is licensed for MS therapy in 
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Germany. Azathioprine is an imidazole derivative 
of 6-mercaptopurine and acts as an immunosup-
pressive antimetabolite. It is a purine antagonist 
and affects DNA replication. It impairs T-cell 
lymphocyte function and is more selective for 
T lymphocytes than for B lymphocytes [Casetta 
et al. 2009]. The Cochrane MS Group concluded 
that azathioprine is an appropriate maintenance 
treatment for patients with MS and could be a fair 
alternative to IFN. It is recommended that cumu-
lative doses do not exceed 600 g due to possibly 
increasing the risk of malignancies [Casetta et al. 
2009].
Methotrexate
Methotrexate (MTX) is a chemotherapeutic agent 
used for the treatment of severe psoriasis, juvenile 
RA (JRA), severe RA, acute lymphoid leukemia 
and other malignancies. MTX reversibly inhibits 
dihydrofolate reductase. Via this mechanism, MTX 
sodium interferes with DNA synthesis, repair 
and cellular replication [Product information: 
methotrexate, 2000, 2005].
On a systematic review of oral MTX for MS, for 
the Cochrane Multiple Sclerosis Group, the 
authors do not recommend the use of MTX for 
progressive MS or RRMS due to a lack of high-
quality evidence. Future trials need to be performed 
using standard outcome measures and objective 
measures, such as MRI [Gray et al. 2004].
Rituximab
Rituximab is FDA approved for the treatment of 
non-Hodgkin’s lymphoma, chronic lymphocytic 
leukemia, refractory moderate to severe RA, 
Wegener’s granulomatosis and microscopic pol-
yangiitis [Prescribing information, 2010]. It is 
EMA approved for diffuse large B-cell lym-
phoma and autoimmune arthritis. Rituximab is 
a chimeric murine/human mAb that targets and 
selectively binds CD20, an antigen present on 
pre-B cells and B cells, but not on antibody-
producing plasma cells or stem cells in the bone 
marrow. By binding CD20, rituximab depletes 
circulating B-cell populations (but not stem cells 
or plasma cells) through a combination of cell-
mediated and complement-dependent cytotox-
icity and possibly promoting apoptosis [Bar-Or 
et al. 2008].
Common side effects of rituximab include naso-
pharyngits, urinary tract infections, nausea, 
leucopenia, fever, fatigue, headache, muscle 
spasms and diarrhea. Cases of PML, severe 
mucocutaneous reactions, tumor lysis syndrome 
and fatal infusion reactions have been docu-
mented. Other severe adverse reactions include 
fulminant hepatitis, hepatic failure, bacterial, 
fungal or viral infections, cardiac arrhythmias, 
renal toxicity and bowel obstruction or perfora-
tion [Prescribing information, 2010].
In a 72-week, open-label phase I trial the safety 
and tolerability of rituximab were evaluated in 26 
patients with RRMS. The authors indicated that 
no serious adverse events were reported in this 
small cohort with active RRMS and all the 
adverse events including infections were mild to 
moderate and did not lead to medication with-
drawal. No efficacy conclusions were noted due 
to the absence of a control group but they noticed 
a reduction in relapses, Gad+ lesions, new T2 
lesion number and T2 lesion volumes through 
72 weeks [Bar-Or et al. 2008]. In a phase II 
randomized, placebo-controlled trial with 104 
patients there was a reduction in Gad+ lesions 
and relapses in patients on rituximab versus pla-
cebo [Hauser et al. 2008]. Rituximab has shown 
efficacy in the treatment of patients with RRMS. 
A recently completed randomized clinical trial 
using a standard dose of rituximab in patients with 
RRMS demonstrated a 91% reduction in the 
number of Gad+ lesions on MRI, as well as a sig-
nificant reduction in the number of clinical 
relapses [Hauser et al. 2008]. In a recent trial of 
patients with PPMS, rituximab appeared to have 
efficacy only in young patients (primarily male) 
with signs of active inflammation on MRI scans 
[Hawker et al. 2009]. Manufacturers of rituximab 
decided not to go forward with phase III trials, 
but other CD20 molecule manufacturers are 
undertaking phase III trials.
Immunoglobulin
While several studies have suggested a beneficial 
effect of intravenous immunoglobulin (IVIG) in 
RRMS [Fazekas et al. 1997; Achiron et al. 1998; 
Lewanska et al. 2002] and CIS [Achiron et al. 
2004] in terms of relapse rate, MRI and disabil-
ity progression, there were limitations in terms 
of methodology and sample size. The most 
recent published trial from the Prevention of 
Relapse with Intravenous Immunoglobulin 
(PRIVIG) study group brought the efficacy of 
IVIG as a preventative agent in MS into ques-
tion [Fazekas et al. 2008]. Current guidelines 
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from the European Federation of Neurological 
Societies recommend that IVIG be considered 
as a second- or third-line therapy in RRMS if 
conventional immunomodulatory therapies are 
not tolerated [Elovaara et al. 2008]. However, 
IVIG is widely used to reduce relapse rate fol-
lowing pregnancy [Achiron et al. 1996; Haas 
and Hommes, 2007].
Corticosteroids
The use of corticosteroids in MS has primarily 
focused on treatment of exacerbations, but there is 
evidence to support the use of steroids as a pre-
ventative therapy. Data from the Optic Neuritis 
Treatment Trial (ONTT) suggest that the use of 
high-dose steroids reduces the risk of development 
of MS at 2 years following the initial optic neuritis 
event [Beck et al.1993]. Further, a randomized, 
controlled phase II trial utilizing pulsed high-
dose methylprednisolone over the course of 5 years 
showed a reduction in brain atrophy, T1 lesion 
volume and disability progression, but failed to 
show a difference in annualized relapse rate or T2 
lesion volume [Zivadinov et al. 2001].
Methylprednisolone in combination with IFN-
β1a did not show reduction in disability progres-
sion compared with IFN-β1a alone [Ravnborg 
et al. for The MECOMBIN study, 2010]. A sim-
ilar study by Sorensen and colleagues showed a 
decrease relapse rate when methylprednisolone 
was used in combination with IFN-β1a subcuta-
neously compared with IFN-β1a alone [Sorensen 
et al. 2009]. The advent of new immunomodulatory 
therapies and concerns for long-term adverse 
effects of steroids largely limit their use as a 
long-term preventative therapy.
What is in the pipeline?
At this time, six new drugs have entered or com-
pleted phase II and III clinical trials, three of which 
are oral drugs. These include laquinimod, teriflu-
nomide and dimethyl fumarate, and three mAbs— 
alemtuzumab, daclizumab and rituximab.
Laquinimod
Laquinimod is an orally administered immu-
nomodulator being studied in patients with 
RRMS and SPMS. The anti-inflammatory prop-
erties of laquinimod are thought to be secondary 
to downregulation of MHC class II gene tran-
scription factors, stimulation of neurotrophic 
factors, activation of the anti-inflammatory IL-4 
pathway in CD4+ T cells, promotion of apopto-
sis in CD8+ T cells and B cells, and suppression 
of the metabolic activity of CD14+ and natural 
killer cells [Thöne et al. 2011]. Therefore, it is 
proposed that laquinimod acts by affecting the 
Th1 to Th2 cytokine shift. Two phase II trials in 
patients with RRMS and SPMS have been com-
pleted, with varying results [Comi et al. 2008; 
Polman et al. 2005]. In the phase III Assessment 
of Oral Laquinimod in Preventing Progression 
in Multiple Sclerosis (ALLEGRO study), laquin-
imod significantly improved clinical and radiologic 
outcomes, resulting in a 23% reduction in relapse 
rate, and a 37% reduction in mean cumulative 
number of Gad+ lesions [Comi et al. 2012b]. 
The Benefit Risk Assessment of Avonex and 
Laquinimod (BRAVO) study is another phase III 
study comparing laquinimod at 0.6 mg/day with 
weekly intramuscular IFN-β1a at 30 μg in patients 
with RRMS. At the 5th Joint Triennial Congress 
of the European and Americas Committees for 
Treatment and Research in Multiple Sclerosis 
(ECTRIMS/ACTRIMS), the results of a rand-
omized, placebo-controlled, double-blind, active-
comparator phase III study, BRAVO, were 
presented. This study did not achieve its primary 
endpoint of reducing the ARR. Laquinimod 
appears to be well tolerated, with only transient 
and dose-dependent increases in liver enzymes 
[Vollmer et al. 2011].
Teriflunomide
Teriflunomide is an oral agent that inhibits the 
synthesis of DNA pyrimidine bases in rapidly 
dividing cells such as T and B cells and mac-
rophages, and may thereby reduce inflammation 
(and likely produce immune suppression). It 
reversibly inhibits dihydroorotate dehydroge-
nase, a key enzyme involved in de novo pyrimi-
dine synthesis. Because activated lymphocytes 
largely depend on de novo pyrimidine synthesis, 
pyrimidine depletion might result in inhibition 
of immune-cell proliferation [Korn et al. 2004]. 
There is some evidence from in vitro studies sug-
gesting that teriflunomide induces Th2-mediated 
anti-inflammatory cytokine activation. A phase 
II study examined the efficacy of teriflunomide 
daily doses of 7 and 14 mg compared with pla-
cebo over 36 weeks in patients with RRMS and 
SPMS. Teriflunomide efficacy was measured by 
the number of new lesions (T2 and Gad+) as 
observed on MRI scans. Active treatment resulted 
in a 61% reduction in MRI activity compared 
 W Castro-Borrero, D Graves et al.
http://tan.sagepub.com 215
with placebo. Teriflunomide was generally well 
tolerated and occurrence of adverse events was 
similar between the two treatment groups. Serious 
adverse events included elevated liver enzyme 
levels, hepatic dysfunction, neutropenia, rhab-
domyolysis and trigeminal neuralgia. A 2-year, 
double-blind, placebo-controlled phase III study 
in RRMS (The Teriflunomide Multiple Sclerosis 
Oral [TEMSO] study) was recently published. 
The study showed that at 7 and 14 mg the ARR 
was approximately 30% compared with placebo. 
Teriflunomide significantly reduced disability 
progression compared with placebo [O’Connor 
et al. 2011].
Dimethyl fumarate
A novel oral therapy under development is dimeth-
ylfumaric acid (BG-12), which is related to fuma-
ric acid, an agent used for many years in psoriasis 
(principally in Europe). BG-12 is thought to 
inhibit immune cells and molecules involved in 
MS attacks on the brain and spinal cord. Fumarates 
appear to modulate a number of oxidative path-
ways and thereby may influence the mechanisms 
by which autoimmune mechanisms provoke 
downstream pathways of tissue damage. In vitro 
studies with the ester dimethyl fumarate (DMF) 
described an inhibitory effect on nuclear factor κB 
dependent transcription of tumor necrosis factor 
α induced genes in human endothelial cells 
[Moharregh-Khiabani et al. 2009]. Although its 
exact MOA is not known, BG-12 is thought to 
inhibit immune cells by stimulating the expression 
of anti-inflammatory cytokines, such as IL-10, 
IL-4 and IL-5. Hence, it is thought that DMF can 
induce a shift from a proinflammatory Th1 to an 
anti-inflammatory Th2 T-cell response [Wierinckx 
et al. 2005]. In addition, BG-12 may have a neuro-
protective therapeutic effect by inducing phase II 
detoxification genes and upregulation of the phase 
II detoxification enzyme, nicotinamide adenine 
dinucleotide phosphate oxidase:quinone oxidore-
ductase-1 [Wierinckx et al. 2005]. In an earlier 
phase II study, compared with placebo, the BG-12 
dose of 240 mg three times a day led to a 69% 
reduction in active inflammation on MRI scans 
from weeks 12 to 24 [Kappos et al. 2008]. A phase 
III pivotal trial showed that 240 mg of BG-12, 
administered twice a day, met the primary study 
endpoint, demonstrating a highly statistically 
significant reduction in relapses in patients with 
RRMS, as well as providing a statistically signifi-
cant reduction in ARR in the number of new or 
newly enlarging T2 hyperintense lesions, in new 
Gad+ lesions, and in the rate of disability progres-
sion at 2 years as measured by the EDSS [Biogen 
Idec, 2011]. Side effects of BG-12 included 
abdominal pain, flushing, headache and fatigue 
[Schimrigk et al. 2006].
Results of the phase III Efficacy and Safety of 
Oral BG00012 in Relapsing-Remitting Multiple 
Sclerosis (DEFINE) trial were presented at the 
5th Joint Triennial Congress of the European and 
Americas Committees for Treatment and Research 
in Multiple Sclerosis (ECTRIMS/ACTRIMS). It 
showed that BG-12 at 24 mg twice or three times 
a day reduced the relapse rate by 49% and 50%, 
respectively.
Alemtuzumab
Alemtuzumab is a mAb that binds to CD52, an 
epitope common to most cells within the immune 
system. Treatment with this agent essentially 
results in an antibody-mediated ablation of the 
circulating immune system. Alemtuzumab binds 
to B and T lymphocytes, resulting in antibody-
dependent cell lysis, and subsequent elimination 
from the bone marrow and blood, with the 
effect lasting up to 16 months. This agent appears 
to rapidly and profoundly establish both clinical 
and radiographic remission of MS; however, 
alemtuzumab has been associated with the 
risk of developing new autoimmune disorders 
(autoimmunity), including thyroiditis, idiopathic 
thrombocytopenic purpura and Goodpasture’s 
syndrome. Cossburn and colleagues found that 
the cumulative risk of autoimmunity in MS fol-
lowing the use of alemtuzumab was 22.2%, most 
frequent between 12 and 18 months following 
the first dose and evident for up to 5 years 
[Cossburn et al. 2011].
Other adverse events associated with alemtu-
zumab include infections, increased cancer risk, 
organ toxicity and infusion-associated hypersen-
sitivity reactions with potentially resultant neu-
tralizing antibodies. Studies of alemtuzumab in 
the treatment of patients with RRMS and SPMS 
have suggested efficacy in the suppression of 
ARR, but with variable results in preventing pro-
gression of disability, depending on stages of the 
disease [Corboy et al. 2010].
The phase II trial CAMMS223 compared alem-
tuzumab (12 or 24 mg intravenously on 5 con-
secutive days during the first month and on 
3 consecutive days at months 12 and 24) with 
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IFN-β1a, 44 μg subcutaneously three times a 
week. Alemtuzumab demonstrated a decrease 
in sustained disability (75% at 12 mg dose and 
67% at 24 mg dose) and a decrease in relapse 
rate (69% at 12 mg and 79% at 24 mg) com-
pared with IFN-β1a subcutaneously [Panitch 
et al. 2008].
Comparison of Alemtuzumab and Rebif 
Efficacy in Multiple Sclerosis Study 1 (CARE 
MS I), a 2 year phase III trial comparing alem-
tuzumab with subcutaneous IFN-β1a in treat-
ment-naïve patients showed a reduction 
in relapse rate by 55% but did not show statistical 
significance regarding slowing disease process. 
A second phase III trial (CARE MS II) is cur-
rently in progress.
Daclizumab
Daclizumab is an engineered human antibody that 
blocks the IL-2 receptor on immune cells. IL-2 is a 
potent immune stimulator and thus by blocking it, 
this therapy putatively dampens immune responses 
(including autoimmune responses).
The clinical benefit derived from daclizumab has 
been linked to the expansion of immunoregula-
tory CD56 natural killer cells, and the resulting 
downregulation of adaptive T-cell responses 
[Bielekova et al. 2006]. A recent open-label phase 
II trial using subcutaneous daclizumab at 2 mg/kg 
in patients with MS whose condition showed an 
inadequate response to IFN-β therapy demon-
strated a 72% reduction in the number of new or 
enlarged contrast-enhancing lesions at week 24 
compared with patients receiving IFN-β alone 
[Wynn et al. 2011]. A phase III trial of daclizumab 
versus IFN-β1a is ongoing (DECIDE study). 
Daclizumab is currently FDA approved for use in 
organ transplant patients.
Ocrelizumab
Ocrelizumab, the humanized version of rituximab, 
is an antibody that targets CD20, a cell surface 
epitope on developing B cells. Upon binding to its 
target, these agents provoke rapid destruction of 
circulating B cells via two principal mechanisms, 
antibody-dependent and complement-dependent 
cellular cytotoxicity.
The effect of CD20 targeting has ramifications for 
both B- and T-cell immune function, and as such, 
these treatments can be associated with risk of 
infection (including PML), and organ toxicity. 
Ocrelizumab, a humanized mAb against human 
CD20, is currently under investigation in a phase 
III program called ORCHESTRA (OPERA I and 
II in RRMS and ORATORIO in PPMS) evaluat-
ing its efficacy in patients with MS. A phase II trial 
comparing ocrelizumb 600 mg and 2000 mg with 
placebo showed a significant reduction in brain 
lesions (89% and 96%, respectively) and ARR 
(80% and 73%, respectively) [Kappos et al. 2011].
Discussion
The pharmacological armamentarium for MS 
has significantly expanded in the past 20 years 
and many new drugs are on the horizon. Each of 
these drugs has their own niche for utilization. 
There are significant data about long-term safety 
and efficacy of all the IFN-β and GA agents which 
should be considered first line in newly diagnosed 
patients. For patients whose condition fails to 
respond to first-line agents (i.e. recurrent clinical 
exacerbations, significant disease burden with 
new and enhancing lesions) or with an aggressive 
disease course at onset alternatives such as natal-
izumab or fingolimod are appropriate. MOAs, 
adverse events and compliance issues should be 
considered when choosing a therapy. Off-label 
agents also have a place for patients who are 
unable to tolerate FDA-approved therapies. These 
agents also offered options for intensification of 
therapy, although large clinical trials are needed 
to determine ideal dosing. The results of efficacy 
and safety profiles of emergent oral and intrave-
nous agents are essential to determine their place 
in the treatment of patients with MS. With the 
advent of new therapies, the need for biomarkers 
that can predict a patient’s response to therapy is 
imperative. More studies are needed to develop 
therapies for halting neurodegeneration, promot-
ing remyelination and promoting neuronal repair.
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